Program
Sodium Chloride
Also written as “Custodiol”, “HalfLytely” and “Sodium chloride”.
Its studies are mostly in Osteoarthritis, Knee · COVID-19 · Aortic Valve Disease · Heart Failure · Corneal Edema, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 20 open or running | phase 1since Aug 31, 2012 | Aug 31, 2012 | none ahead |
| aspen-global-incorporated | 10 open or running | phase 4since Jan 29, 2019 | Jan 29, 2019 | none ahead |
| Eye-yon Medical | 10 open or running | no phasesince Jan 11, 2016 | Jan 11, 2016 | none ahead |
| Lumos Pharma | 10 open or running | phase 1since Dec 10, 2017 | Dec 10, 2017 | none ahead |
| Nova Vita Laboratory | 11 open or running | phase 2since Sep 17, 2024 | Sep 17, 2024 | Apr 1, 2027phase 2 · NCT06606561 |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2012First study: phase 1 study in Diabetes MellitusNew to Novo NordiskNovo Nordisk · NCT01680328 · 82 enrolled · Germany
- Nov 6, 2012Phase 1 study in Diabetes MellitusNovo Nordisk · NCT01730014 · 70 enrolled · Germany
- Jan 11, 2016Eye-yon Medical's first study: no phase study in Corneal EdemaNew to Eye-yon MedicalEye-yon Medical · NCT02660151 · 68 enrolled · Israel, Poland
- Dec 10, 2017Lumos Pharma's first study: phase 1 study in HealthyNew to Lumos PharmaLumos Pharma · NCT03372239 · 48 enrolled · Canada
- Jan 29, 2019aspen-global-incorporated's first study: phase 4 study in Injection Site ReactionNew to aspen-global-incorporatedaspen-global-incorporated · NCT03841396 · 15 enrolled
- Sep 17, 2024Nova Vita Laboratory's first study: phase 2 study in Osteoarthritis, KneeNew to Nova Vita LaboratoryNova Vita Laboratory · NCT06606561 · 24 planned · United States
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Osteoarthritis, KneeNova Vita Laboratory · NCT06606561
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06606561Osteoarthritis, Knee · United States | 2 | Not yet recruiting | Nova Vita Laboratory | Apr 1, 2027 | 24 |
| NCT03841396Injection Site Reaction | 4 | Completed | aspen-global-incorporated | Jul 15, 2016 | 15 |
| NCT03372239Healthy · Canada | 1 | Completed | Lumos Pharma | Jan 25, 2018 | 48 |
| NCT02660151Corneal Edema · Israel, Poland | – | Completed | Eye-yon Medical | Oct 2018 | 68 |
| NCT01730014Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Jul 2013 | 70 |
| NCT01680328Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Oct 2012 | 82 |
How it is read
Names in the registry
- “Custodiol”, 4 entries
- “HalfLytely”, 3 entries
- “Sodium chloride”, 2 entries
- “PLENVU®”, 1 entry
- “0.9% Sodium Chloride Injection, USP”, 1 entry
Conditions, from the studies’ own filings
- Osteoarthritis, Knee, 1 study
- COVID-19, 1 study
- Aortic Valve Disease, 1 study
- Heart Failure, 1 study
- Corneal Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.